A ctivation of naive T lymphocytes induces them to proliferate and differentiate into effector T cells, which mediate and regulate acquired immune responses. This activation process is dependent on the formation of a trimolecular complex among MHC molecules, Ag-derived peptide, and a specific TCR. Formation of this complex during T cell-APC interaction induces three major signaling pathways within the T cell cytoplasm: protein kinase C (PKC) 3 activation, calcium signaling, and p21 ras activation (1) . It is well established that two major subsets of effector T cells exist which mediate distinct functions in the immune system. Development of these subsets, CD4 Th1 and Th2, explains the phenomenon of immune deviation in which an immune response is dominated by either Ab production or cellmediated immunity (2) . More recently, the CD8 T cell compartment has been shown to consist of comparable T cell subsets: T cytotoxic (Tc) 1 and Tc2 (3) (4) (5) , such that both CD4 and CD8 T effector cells can be defined as type 1 (IFN-␥ secreting) or type 2 (IL-4 secreting). Development of these subsets is known to be important in resistance to various infectious agents (6) and in the development of immune-mediated autoimmune and allergic diseases (7) (8) (9) (10) .
The cytokines IL-12 and IL-4 are widely thought to be the major factors inducing T cells to develop into type 1 or type 2 cells, respectively (4, (11) (12) (13) . However, it has long been recognized that the nature or intensity of the TCR-transduced stimulus can regulate T cell development. Altering the dose of antigenic peptide used to trigger TCR-transgenic CD4 T cells can determine their Th1/Th2 phenotype (14, 15) , and altering the MHC molecule or sequence of the peptide ligand can also modulate cytokine production (16 -18) . Recent use of single-cell analysis has shown that mixtures of Th1 and Th2 cells can be generated in the same cytokine environment (19) . These data suggest that signals generated by TCR ligation can determine the differentiation of effector T cells independently of exogenous cytokines. How this is achieved is unknown, but it has been proposed that the avidity of the TCR-peptide-MHC interaction, determined by a combination of TCR-binding affinity and ligand density on APC, determines the Th1/Th2 balance (20) . In the current study, we present a mechanism whereby the balance of intracellular signals induced via TCR stimulation is a primary influence on the decision a developing cell makes between the type 1 and type 2 pathways. We present data indicating that altered peptide ligands can induce a different balance of PKC and calcium signaling via the TCR that can favor type 2 effector cell development, and that Tc1 and Tc2 clones retain altered signaling characteristics when fully differentiated. Artificial manipulation of TCR signals could dramatically alter the type 1/type 2 balance in both murine and human T cell responses in vitro.
Materials and Methods

Mice and murine T cell purifications
Four-to 8-wk-old BALB/c mice were purchased from Harlan Olac (Bicester, U.K.). TCR-transgenic mice expressing a V␤5 transgene specific for OVA peptide 257-264 (OVA 257 ) in the context of H-2K b (21) (OT1 mice) were bred in our animal facility. Murine CD4 and CD8 T cells (Ͼ98% pure) were purified from lymph node cells by positive selection using a magnetic cell separation system (Miltenyi Biotech, Bisley, U.K.) according to the manufacturer's instructions.
Human T cell purification and Tc1/Tc2 clones
Human PBMC were obtained from healthy volunteers (South Thames Blood Transfusion Centre, London, U.K.). CD4 or CD8 T cells were purified by positive selection using magnetic beads and Detachabead Ab (Dynal, Wirral, U.K.) according to the manufacturer's instructions. Tc1 and Tc2 clones (22) were derived from purified human CD8 T cells by limiting dilution and successive rounds of PHA (5 g/ml) and IL-2 (50 U/ml) stimulation in the presence of irradiated feeder cells. They were classified into Tc1 and Tc2 subsets based on intracellular staining for IL-4 and IFN-␥ after anti-CD3/CD28 stimulation.
Cell culture
Murine CD4 or CD8 T cells were cultured at 5 ϫ 10 5 /ml in DMEM ϩ 10% FBS ϩ L-glutamine (2 mM), HEPES (1 mM), nonessential amino acids (1 mM each), gentamicin (50 g/ml) and 2-ME (50 M). Twenty-four-well plates were coated with anti-CD3 mAb (145-2C11; PharMingen, Oxford, U.K.) at 1 g/ml in PBS for 2 h before addition of T cells. Recombinant murine IL-4 (Serotec, Oxford, U.K.), human IL-4 (PharMingen), recombinant murine IL-12, recombinant human IL-12, or anti-mouse IL-12 (R&D Systems, Abingdon, U.K.) were added. Human T cells were cultured at 1 ϫ 10 6 /ml in RPMI 1640 ϩ 10% human AB serum ϩ additives as for DMEM. PMA, ionomycin (Sigma, Poole, U.K.), cyclosporin A (CsA), and bisindolylmaleimide I (BIS) (Calbiochem, Nottingham, U.K.) were added at various concentrations as indicated.
Intracellular cytokine staining
Murine T cells were washed after 4 days of culture and restimulated with PMA (10 ng/ml) and ionomycin (400 ng/ml) in the presence of the protein transport inhibitor monensin (3 M; Sigma) for 5 h. Human T cells were washed after 4 days of culture, restimulated with PMA (10 ng/ml) and ionomycin (400 ng/ml) for 18 h, and then cultured for another 18 h after addition of brefeldin A. Murine cells were fixed/permeabilized using Perm/ Fix solution (PharMingen), washed, and stained for intracellular IL-4 and IFN-␥ (PE-labeled anti-IL-4 BVD4--D11, FITC-labeled anti-IFN-␥ XMG1.2) according to the manufacturer's protocol. Human cells were fixed with 4% formaldehyde, washed, and permeabilized in 0.5% saponin/1% BSA in PBS before staining with anti-IL-4-PE (MP4-25D2; PharMingen) ϩ anti-IFN-␥-FITC (25723.11; Becton Dickinson, Mountain View, CA). Cells were analyzed by flow cytometry (FACScalibur; Becton Dickinson). Isotype control mAbs and nonrestimulated T cells were used as negative controls to set quadrant markers.
Calcium flux measurements
Lymph node cells from TCR-transgenic mice were labeled with aminocarboxyindolylphenoxy-aminomethylphenoxy-ethane-tetraacetic acid (INDO-1/AM) calcium-sensitive dye (Calbiochem) at 4 g/ml for 30 min at 37°C. The cells were washed and 5 ϫ 10 5 were added to 2.5 ϫ 10 6 C57BL/6 splenocytes that had been cultured overnight in the presence of 10 g/ml OVA 257 , pTE1, or control peptides, and then activated with 10 g/ml LPS for 2 h. Cells were briefly centrifuged, incubated at 37°C for 2-12 min, and analyzed for intracellular calcium by flow cytometry using a UV laser with detection of the ratio of blue:green (395 nm:530 nm) fluorescence as an indicator of intracellular calcium (FACS Vantage; Becton Dickinson). Adequate INDO-1 loading was confirmed by addition of ionomycin (1 g/ml).
PKC/protein kinase D (PKD) analysis
C57BL/6 splenocytes ( 10 7 ) were placed onto Cell-Tak (Becton Dickinson)-coated tissue culture dishes and left to adhere at 37°C for 2 h in the presence of 10 g/ml peptide. The cells were then rinsed twice with culture medium and 10 7 TCR-transgenic lymph node cells were added to the adherent splenocytes. After a 45-min incubation at 37°C, nonadherent cells were pelleted and the cytoplasmic fraction obtained by lysing in 50 ml of 20 mM Tris-HCl (pH 7.5), 2 mM EDTA, 10 mM EGTA, 50 mM 2-ME, 1 mM PMSF, 5 mg/ml leupeptin, 5 mg/ml aprotinin, 5 mg/ml trypsin inhibitor, and 25 mM benzamidine. This was sonicated and centrifuged and the supernatant was stored. For the membrane fraction, the pellet was collected and resuspended in the same buffer with addition of 1% Triton X-100. The pellet was sonicated and centrifuged. Samples were boiled for 5 min in 2ϫ Laemmli sample buffer and then run on 4 -15% linear gradient polyacrylamide gels (Bio-Rad, Herts, U.K.). Proteins were blotted onto nitrocellulose membranes, blocked with 5% skimmed milk in PBS ϩ 0.1% Tween 20, and then incubated with either anti-PKC-␣, -␤, and -␥ mAb (Santa Cruz Biotechnology, Calne, U.K.) or anti-phospho-PKD (gift from Dr. D. Cantrell, Imperial Cancer Research Fund, London, U.K.). After washing, blots were incubated with HRP-conjugated Ab (anti-mouse for anti-PKC or anti-rabbit for anti-phospho-PKD; Amersham Pharmacia Biotech, Little Chalfont, U.K.). The bands were visualized using enhanced chemiluminescence (Amersham Pharmacia Biotech).
IC 50 measurements
Cells were cultured as described above in triplicate 0.2-ml cultures. Serial 2-fold dilutions of BIS or CsA were added. After 3 days, 0.5 Ci/well [ 3 H]thymidine was added for 6 h. Cells were harvested, 3 H incorporation was measured, and inhibition curves were plotted for calculation of IC 50 values. TCR-transgenic cells were stimulated with altered peptide ligand (APL) at 10 g/ml; data are presented as means Ϯ SEM from three independent experiments. Human CD8 T cell clones were stimulated with anti-CD3/CD28; data are presented as means Ϯ SEM from groups of five individual clones.
Results
PMA provides a type 2-promoting stimulus to CD4 and CD8 T cells
We first assessed the development of type 1 and type 2 effector T cells using purified murine CD4 and CD8 T cells stimulated with anti-CD3/CD28 Abs. To determine the phenotype of effector cells, we restimulated them after 4 days with PMA ϩ ionomycin in the ϩ /IFN-␥ ϩ . Similar results were obtained if cells were restimulated with anti-CD3 ϩ anti-CD28 ϩ monensin; however, PMA/ionomycin induced higher levels of staining and was used throughout this study.
From the experiments illustrated in Fig. 1 , it became apparent that addition of cytokines to T cell cultures was less effective at directing T cell development than the nature of the activating stimulus itself. CD8 T cells were strongly biased toward the type 1 pathway compared with CD4 T cells and addition of IL-4, and neutralization of endogenous IL-12 was insufficient to induce substantial numbers of Tc2 effectors (Fig. 1a) . However, addition of PMA, which stimulates PKC activity, was able to switch the cells toward the Tc2 phenotype in the presence of IL-4. CD4 T cells stimulated with anti-CD3/CD28 alone developed into mixtures of Th1 and Th2 cells, although percentages of cytokine-positive cells were low (Fig. 1b) . Addition of IL-4 induced a modest increase in IL-4 ϩ cells but failed to induce a polarized type 2 population, whereas IL-12 resulted in an increased proportion of Th1 cells. In contrast, addition of PMA caused a dramatic switch toward Th2 development, even when exogenous IL-12 was present in the culture (data not shown). The increase in IL-4 production was not due to more effective T cell stimulation induced by PMA, since it could be neutralized by addition of ionomycin in both CD4 and CD8 cells.
Differential stimulation of T cells with PMA vs ionomycin regulates effector cell development
The results illustrated in Fig. 1 led us to test the hypothesis that the balance of PKC activity vs calcium signaling was important in type 1/type 2 development by stimulating T cells with different concentrations of both PMA and ionomycin (which triggers an influx of calcium into the cells). The results (Fig. 2) clearly indicate that when unprimed T cells received a strong calcium signal and a weak PKC signal (i.e., when stimulated with a high concentration of ionomycin combined with a low concentration of PMA), they preferentially developed into type 1 effector cells. In contrast, strong PKC stimulation combined with a weaker calcium signal (high PMA concentration and low ionomycin concentration) resulted in type 2 cells. Similar results were obtained with both CD8 and CD4 T cells (data not shown). Comparable effects of the PMA: ionomycin ratio were obtained when a similar experiment was performed using human CD8 T cells (Fig. 2b ) prepared from peripheral blood and stimulated in the presence of IL-4 and IL-12. These data indicated that human T cell differentiation is regulated in a similar fashion to murine cells, with PKC activity being critical to the development of Tc2 effector cells. Cells expressing the type 0 phenotype occurred at a high frequency in the human T cell cultures but were rare in the murine system.
Partial inhibition of PKC or calcium signaling redirects T cell development
Having established the effects of indiscriminate stimulation of PKC and calcium signals on the T effector generation, we considered whether T cell development could be redirected by partial inhibition of the PKC or calcium signals generated via the TCR complex itself. We used two selective inhibitors in T cell cultures: CsA, a specific inhibitor of calcineurin (a vital component of the calcium pathway), and BIS, a selective PKC inhibitor (23) . The addition of low concentrations of CsA was able to redirect anti-CD3-induced development of CD4 T cells from Th1 to Th2 (Fig.  3) . In contrast, addition of BIS resulted in type 1 effector cells when culture conditions favoring type 2 development were used. Inhibitors were able to redirect T cell development only at a narrow range of concentrations, and higher concentrations of both CsA or BIS blocked outgrowth of both type 1 and type 2 effectors (data not shown). To confirm that the polarized T cells had an altered phenotype, we also performed staining for IL-2, which correlated with IFN-␥ staining, and IL-10, which correlated with IL-4 (data not shown). These data confirm that the balance of PKC and calcium signaling induced through the TCR complex can direct T cell differentiation.
Altered TCR ligands regulate Tc1/Tc2 development
Having demonstrated the effects of artificial manipulation of PKC and calcium signaling, we tested whether APL for the TCR, which have been reported to preferentially induce Th2 development (17, 24) , might stimulate distinct patterns of these signals in naive T cells. It has been demonstrated that APL induce lowered and less sustained calcium transients in CD4 TCR-transgenic T cells (25) . We cultured TCR-transgenic lymph node cells with conventional OVA 257 peptide or APL and determined the type 1/type 2 phenotype of effector cells produced after 4 days. These cells were Ͼ95% CD8 ϩ after the culture period, and all peptides induced comparable levels of T cell proliferation at the concentrations used. In the absence of PMA, all peptides generated Tc1 type effectors with only very low percentages of Tc2 cells detectable (Ͻ1%; data not shown). In the presence of PMA, however, OVA 257 peptide stimulation generated Tc1 effectors, whereas APL stimulation generated mixtures of both Tc1 and Tc2 cells (Fig. 4) . The partial agonist G4 and agonist/antagonist peptide pTE1 induced the greater percentages of Tc2 effectors, although Tc1 cells were still present. The effect of altered peptides appeared to be independent of the effect of Ag dose, since using low doses of OVA 257 peptide (0.03-0.3 g/ml) had comparatively little effect on type 1/type 2 differentiation (data not shown).
Altered peptides induce differential PKC/calcineurin signaling
To investigate whether the effects of altered peptides were due to an altered balance of PKC and calcium signaling after TCR engagement, we wished to directly measure PKC and calcium signaling in TCR-transgenic cells stimulated with peptides. Calcium signaling was measured in peptide-stimulated TCR-transgenic T cells by flow cytometry using the calcium-sensitive dye INDO-1/AM (Fig. 5a) . Calcium flux within the T cell cytoplasm was detectable in small percentages of the cells a few minutes after stimulation with OVA 257 peptide, and was considerably weaker in cells stimulated with the pTE1 peptide. A negative control peptide failed to induce significant calcium signaling. We were unable to measure PKC activity directly in these naive T cells, but were able to assess both PKC translocation from the cytosol to membrane (Fig. 5b) , an indicator of activation (26) , and phosphorylation of PKD (PKC; Fig. 5c ) by Western blot. PKD lies downstream of phospholipase C in TCR signaling and is directly activated by PKC (27) . Stimulation of TCR-transgenic cells with OVA 257 induced both PKC translocation and PKD phosphorylation. The APLs pTE1 and G4 induced similar levels of PKC translocation but PKD phosphorylation was not detectable with these stimuli.
Such direct measurements of signaling in naive T cells were not sufficiently quantitative to confirm our hypothesis that an altered balance of signals is induced by APL. We therefore used an alternative approach and determined the concentrations (IC 50 ) of CsA and BIS required to block T cell activation as an indication of the levels of calcium and PKC signaling occurring after APL stimulation. IC 50 values were determined by adding the drugs at varying doses to peptide-stimulated T cells and measuring their proliferation (Table I ). The ratio IC 50 (BIS):IC 50 (CsA) was greater for a partial agonist (G4) and an antagonist/agonist APL (pTE1) than for the conventional OVA 257 peptide or an unrelated agonist peptide (p53). This difference was mainly due to the weaker calcium signaling induced by the altered peptides. These data are broadly consistent with the direct measurements of PKC and calcium signaling, suggesting that such measurements are a good indication of levels of signaling induced. Taken together, the data suggest that CsA was added at various doses to type 1 cultures and BIS to type 2 cultures; the optimum doses are shown. After 4 days, the T cell phenotype was assessed as in Fig. 1 . Culture conditions used were: a, anti-CD3/CD28 ϩ IL-4 (10 ng/ml) ϩ anti-IL-12 (2 g/ml); b, anti-CD3/CD28 ϩ IL-4 (10 ng/ml) ϩ anti-IL-12 (0.5 g/ml) ϩ PMA (10 ng/ml); c, anti-CD3/CD28 ϩ IL-4 (10 ng/ml) ϩ IL-12 (1 ng/ml); and d, anti-CD3/CD28 ϩ IL-4 (10 ng/ml) ϩ IL-12 (2.5 ng/ml) ϩ PMA (10 ng/ml). Addition of CsA to type 2 cultures or addition of BIS to type 1 cultures did not redirect development (data not shown). Results shown are representative of several independent experiments. altered residues in the TCR peptide ligand induce distinct balances of PKC/calcium signals through the TCR which can favor type 2 development.
Human Tc1 and Tc2 T cell clones exhibit distinct patterns of calcium signaling
It has been reported previously that CD4 Th1 clones exhibited much stronger calcium signals than comparable Th2 clones (28, 29) given the same stimulus. This suggested to us that the differential PKC/calcium signaling that induces initial development of type 1 vs type 2 cells is retained in fully differentiated effectors after long-term stimulation. We therefore tested whether different subsets of CD8 T cell clones exhibit distinct patterns of PKC/ calcium signaling using a similar analysis to that described for APL stimulation. Human Tc1 and Tc2 clones were stimulated with anti-CD3/CD28, and IC 50 values for BIS and CsA were determined (Table II) . The data indicated that Tc2 cells exhibited weaker calcium/calcineurin signaling (as indicated by their resistance to CsA) than Tc1 clones, while there was little difference in the amount of PKC activity induced in the two subsets. The balance of the two signaling pathways thus appeared related to the cytokine profile of the clones.
Discussion
Since the original description of the Th1 and Th2 subsets of CD4 T cells (30) , many studies have examined the role of cytokines on commitment of T cells to different cytokine profiles. It has become clear that the balance of IL-4 and IL-12/IFN-␥ present during T cell priming can result in polarization of T cells toward the Th2 or Th1 phenotypes, respectively. Some of the molecular signaling pathways induced via the IL-4 and IL-12 receptors, which control Th1/Th2 development, have now been identified (31) . However, signals from the TCR have also been proposed as modulators of T cell subset development based on observations that the dose and nature of Ag can result in altered cytokine production (14, 15, 25) . Here, we present data which suggest a mechanism whereby the TCR can regulate T cell differentiation. We show that TCR-mediated signals can direct T cell development when both IL-4 and IL-12 are present, i.e., when culture conditions permit the expansion of both type 1 and type 2 effector cells. Our data provide potential additional intracellular molecules which could be targeted for modulation of type 1/type 2-immune responses. FIGURE 4. APL regulate Tc1/Tc2 development of TCR-transgenic CD8 T cells. Lymph node cells from transgenic mice were stimulated for 4 days in the presence of the indicated peptides at 10 g/ml ϩ IL-4 (10 ng/ml), anti-IL-12 (2 g/ml), and PMA (10 ng/ml). Cells (Ͼ95% CD8 ϩ ) were then restimulated and cytokine analysis was performed as in Fig. 1 . Results are representative of several independent experiments. Single-cell analysis of cytokine production using T cell-cloning procedures has indicated that individual T cells can produce virtually any combination of type 1 or type 2 cytokines, such that the type 1/type 2 phenotypes can only be ascribed to populations of T cells generated under polarizing conditions (32, 33) . The development of intracellular cytokine-staining techniques has allowed individual T cell phenotypes to be characterized during primary effector development (3-5 days (11)) rather than after long-term culture, when certain T cell subsets may have outgrown others. We have therefore chosen to use this technique to examine the role of TCR-mediated signaling pathways in the generation of effector cells. Similar approaches using TCR-transgenic CD4 cells indicate that complete polarization of T cells into the type 1 or type 2 phenotypes after short-term culture requires neutralization of endogenous IL-4 or IL-12/IFN-␥ in addition to provision of exogenous cytokines (34) . In our hands, manipulation of the primary T cell stimulus is required to alter the type 1/type 2 balance in a substantial proportion of developing T cells in the absence of anticytokine Abs. This suggests that although IL-12 or IL-4 are necessary for efficient type 1 and type 2 effector generation, TCRdependent factors provide a distinct form of regulation.
Our conclusion that the balance of PKC and calcium signals induced via the TCR can direct T cell differentiation is based on three independent lines of evidence. First, that stimulation of PKC activity with PMA and induction of calcium flux with ionomycin exert opposing effects on type 1/type 2 cytokine production. However, these agents bypass the TCR and could provide additional or more potent stimuli. Second, we have shown that similar effects can be observed by partially blocking PKC or calcineurin activity induced by TCR activation using suboptimal concentrations of specific inhibitors. Taken together, these data indicate that the balance of signals rather than the strength of stimulation mediate the observed effects on cytokine production. They also suggest that such skewing effects are mediated by known TCR-induced pathways rather than by nonspecific modulation of other biochemical signals by the drugs used. Since p21 ras is also regulated by PKC (1), it remains unclear whether the PKC signal generated by phospholipase C or the p21 ras pathway is the more important in inducing type 2 development. Further studies are required to identify more precisely the signaling molecules involved. The third line of evidence using APL demonstrates that physiological ligands of the TCR can result in differential signaling which could account for their effects on T cell differentiation. Our data confirm those in CD4 cells indicating that APL induce reduced calcium signaling (24) . However, we propose that weak agonist ligands can simultaneously induce relatively high PKC signals which promote type 2 effector development. Although this is the first demonstration to our knowledge that APL can control development of Tc1 vs Tc2 CD8 cells, it should be noted that addition of PMA was required to generate large proportions of Tc2 cells in these experiments. Thus, the effect of APL may be insufficient to overcome the bias of CD8 cells toward the type 1 cytokine pattern in physiological situations.
It is interesting to note that human peripheral blood T cells could be induced to express altered cytokine phenotypes by differential PMA/ionomycin stimulation. Since human T cells contain a high proportion of primed or memory T cells which are the major producers of cytokines, whereas murine lymph node T cells are predominantly naive, these data open the possibility that effector cell generation from both naive and memory precursors is regulated via the PKC and calcium signals. The patterns of signaling in human type 1 and type 2 clones support the conclusion that TCR signaling directs T cell subsets. It has long been known that Th2 clones show reduced calcium flux after activation compared with Th1 clones (28) . Our results confirm this observation in CD8 cells and provide an explanation for this phenomenon, i.e., that the signals which induce type 1 and type 2 effector cells are used by the same cells after commitment to a particular T cell subset.
It is now clear that mixtures of type 1 and type 2 T cells can be induced in the same cytokine environment (19) , and that there is a stochastic element to the acquisition of cytokine phenotype by T cells (32) . We considered the possibility that this phenomenon was due to differential TCR signaling. However, TCR-independent stimulation with PMA and ionomycin also induced mixtures of type 1 and type 2 cells (Fig. 2) . Thus, it appears that as for cytokines, TCR stimuli can only increase or decrease the probability that type 1 or type 2 cytokines will be produced by the resulting effectors and cannot activate their production in all cells.
The mechanisms via which PKC and calcium/calcineurin signaling induce type 1 or type 2 cytokine production remain unclear and require further study. One possibility is that they induce differential cytokine production which subsequently alters T cell subset development. However, since their effects are observed in the presence of excess exogenous IL-4 and IL-12, it seems unlikely that these two cytokines are involved, although a role for other cytokines cannot be ruled out. A more likely possibility is that signals downstream of PKC and calcineurin directly result in preferential type 1 or type 2 cytokine gene expression, perhaps via expression of transcription factors associated with Th2 cells (35, 36) . It seems likely that members of the NF-AT/AP-1 family of transcription factors are involved in this process, since these are activated by PKC and calcineurin and are required for expression of Th1 and Th2 cytokine genes (37, 38) . Once these cytokines have been produced, cross-regulation will ensure continued polarization and commitment of the cells to the type 1 or type 2 subsets after repeated cell division (39, 40) . Taken together, these data provide a novel mechanism whereby the nature of T cell-stimulating ligands could control the type of T cell response that occurs in the periphery. It seems likely that highly polarized type 1/type 2-inducing cytokine environments rarely occur during a primary T cell response in vivo, since dendritic cells are potent producers of IL-12, and low frequencies of IL-4-producing T cells in unprimed T cell populations can support Th2 development (41) . Differential TCR signaling could therefore be critical for the establishment of appropriate type 1/type 2 effector functions on first exposure to Ag. The pivotal role of the PKC and calcium/calcineurin pathways identified here suggests that T cell responses in vivo could be modulated by low doses of CsA/FK506 or PKC inhibitors. Indeed, CsA treatment has been shown to enhance the Th2-associated IgE Ab response in vivo and in vitro (42, 43) . PKC inhibitors are a more recently developed class of drug which may prove to be potent inhibitors of Th2 responses. In light of the current data, such manipulation may be more likely to result in a lasting switch in T cell subset commitment than strategies aimed at cytokines or their receptors.
